Triple negative breast cancer Trials in Beijing, China
Conditions / Triple negative breast cancer / Beijing, China
Triple negative breast cancer is a medical condition with active clinical research programs worldwide.
38 total trials for this combination
Showing top 10 of 38 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02225470 | Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | COMPLETED | PHASE3 |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | TERMINATED | PHASE3 |
| NCT02580747 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | UNKNOWN | PHASE1 |
| NCT05909332 | Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) | RECRUITING | PHASE3 |
| NCT07018427 | Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | RECRUITING | PHASE1/PHASE2 |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) | COMPLETED | PHASE3 |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1 |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | COMPLETED | PHASE1/PHASE2 |